Costa LJ, Hari PN, Kumar SK (2016) Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity. Leuk Lymphoma 57(12):2827–2832. https://doi.org/10.3109/10428194.2016.1170828

Article  PubMed  Google Scholar 

Del Giudice ML, Gozzetti A, Antonioli E, Attucci I, Pengue L, Cassano Cassano R, Ghio F, Orciuolo E, Simoncelli M, Bocchia M, Galimberti S, Buda G (2022) Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: a retro-prospective observational study. Eur J Haematol 109(4):373–380. https://doi.org/10.1111/ejh.13819

Article  CAS  PubMed Central  PubMed  Google Scholar 

Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosinol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ, Investigators E (2016) Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 17(1):27–38. https://doi.org/10.1016/S1470-2045(15)00464-7

Article  CAS  PubMed  Google Scholar 

Jelinek T, Maisnar V, Pour L, Spicka I, Minarik J, Gregora E, Kessler P, Sykora M, Frankova H, Adamova D, Wrobel M, Mikula P, Jarkovsky J, Diels J, Gatopoulou X, Vesela S, Besson H, Brozova L, Ito T, Hajek R (2018) Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients. Curr Med Res Opin 34(5):775–783. https://doi.org/10.1080/03007995.2017.1410121

Article  CAS  PubMed  Google Scholar 

Kastritis E, Terpos E, Dimopoulos MA (2022) How I treat relapsed multiple myeloma. Blood 139(19):2904–2917. https://doi.org/10.1182/blood.2020008734

Article  CAS  PubMed  Google Scholar 

Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blade J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328–e346. https://doi.org/10.1016/S1470-2045(16)30206-6

Article  PubMed  Google Scholar 

Lee JH, Kim S-H, Lee YJ, Min CK, Park S-S, Kim K, Shin D-Y, Park JS, Shin H-J, Lee HS, Jo J-C, Lee WS, Yhim H-Y, Kwak J-Y, Jy L, Byun JM, Choi YS (2019) The comparison of Carfilzomib, and dexamethasone versus pomalidomide-based combination chemotherapy after a 2nd-line therapy in relapsed and refractory multiple myeloma patients. Clin Lymphoma Myeloma Leuk 19(10):e264–e265. https://doi.org/10.1016/j.clml.2019.09.437

Article  Google Scholar 

Lee HS, Kim K, Lee JJ, Yoon SS, Bang SM, Kim JS, Eom HS, Yoon DH, Lee Y, Shin HJ, Park Y, Jo JC, Lee WS, Do YR, Mun YC, Lee MH, Kim HJ, Kim SH, Kim MK, Lim SN, Park SK, Yi JH, Lee JH, Min CK, Korean Multiple Myeloma Working P (2021) Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Int J Hematol 113(1):81–91. https://doi.org/10.1007/s12185-020-02988-6

Article  CAS  PubMed  Google Scholar 

Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, Minnema MC, Lassen U, Krejcik J, Palumbo A, van de Donk NW, Ahmadi T, Khan I, Uhlar CM, Wang J, Sasser AK, Losic N, Lisby S, Basse L, Brun N, Richardson PG (2015) Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 373(13):1207–1219. https://doi.org/10.1056/NEJMoa1506348

Article  CAS  PubMed  Google Scholar 

Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Blade J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM (2016) Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 387(10027):1551–1560. https://doi.org/10.1016/S0140-6736(15)01120-4

Article  CAS  PubMed  Google Scholar 

Moreau P, Mateos MV, Berenson JR, Weisel K, Lazzaro A, Song K, Dimopoulos MA, Huang M, Zahlten-Kumeli A, Stewart AK (2018) Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol 19(7):953–964. https://doi.org/10.1016/S1470-2045(18)30354-1

Article  CAS  PubMed  Google Scholar 

Nathwani N, Bertamini L, Banerjee R, Gay F, Shah N, Krishnan A (2021) When and how to treat relapsed multiple myeloma. Am Soc Clin Oncol Educ Book 41:358–375. https://doi.org/10.1200/EDBK_320129

Article  PubMed  Google Scholar 

Nunes AT, Annunziata CM (2017) Proteasome inhibitors: structure and function. Semin Oncol 44(6):377–380. https://doi.org/10.1053/j.seminoncol.2018.01.004

Article  CAS  PubMed  Google Scholar 

Onda Y, Kanda J, Kaneko H, Shimura Y, Fuchida SI, Nakaya A, Itou T, Yamamura R, Tanaka H, Shibayama H, Shimazu Y, Uchiyama H, Yoshihara S, Adachi Y, Matsuda M, Hanamoto H, Uoshima N, Kosugi S, Ohta K, Yagi H, Kanakura Y, Matsumura I, Hino M, Nomura S, Shimazaki C, Takaori-Kondo A, Kuroda J, Kansai Myeloma F (2022) Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis. Ther Adv Hematol. https://doi.org/10.1177/20406207221104584

Article  PubMed Central  PubMed  Google Scholar 

Orlowski RZ, Moreau P, Niesvizky R, Ludwig H, Oriol A, Chng WJ, Goldschmidt H, Yang Z, Kimball AS, Dimopoulos M (2019) Carfilzomib-dexamethasone versus bortezomib-dexamethasone in relapsed or refractory multiple myeloma: updated overall survival, safety, and subgroups. Clin Lymphoma Myeloma Leuk 19(8):522-530 e521. https://doi.org/10.1016/j.clml.2019.04.018

Article  PubMed  Google Scholar 

Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P (2015) Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol 33(26):2863–2869. https://doi.org/10.1200/JCO.2015.61.2267

Article  CAS  PubMed Central  PubMed  Google Scholar 

Richardson PG, San Miguel JF, Moreau P, Hajek R, Dimopoulos MA, Laubach JP, Palumbo A, Luptakova K, Romanus D, Skacel T, Kumar SK, Anderson KC (2018) Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J 8(11):109. https://doi.org/10.1038/s41408-018-0141-0

Article  PubMed Central  PubMed  Google Scholar 

Shah JJ, Abonour R, Gasparetto C, Hardin JW, Toomey K, Narang M, Srinivasan S, Kitali A, Zafar F, Flick ED, Rifkin RM (2017) Analysis of common eligibility criteria of randomized controlled trials in newly diagnosed multiple myeloma patients and extrapolating outcomes. Clin Lymphoma Myeloma Leuk 17(9):575-583 e572. https://doi.org/10.1016/j.clml.2017.06.013

Article  PubMed  Google Scholar 

Song X, Cong Z, Wilson K (2016) Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States. Curr Med Res Opin 32(1):95–103. https://doi.org/10.1185/03007995.2015.1105202

Article  CAS  PubMed  Google Scholar 

Sverrisdottir IS, Rognvaldsson S, Thorsteinsdottir S, Gislason GK, Aspelund T, Turesson I, Bjorkholm M, Gregersen H, Hveding Blimark C, Landgren O, Kristinsson SY (2021) Comorbidities in multiple myeloma and implications on survival: a population-based study. Eur J Haematol 106(6):774–782. https://doi.org/10.1111/ejh.13597

Article  PubMed  Google Scholar 

Toppila I, Kysenius K, Miettinen T, Lassenius MI, Lievonen J, Anttila P (2022) Comorbidity characteristics of multiple myeloma patients diagnosed in Finland 2005–2016. Ann Hematol 101(11):2485–2495. https://doi.org/10.1007/s00277-022-04959-9

Article  PubMed Central  PubMed  Google Scholar 

Usmani SZ, Diels J, Ito T, Mehra M, Khan I, Lam A (2017) Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: an adjusted treatment comparison. Am J Hematol 92(8):E146–E152. https://doi.org/10.1002/ajh.24781

Article  CAS  PubMed Central  PubMed  Google Scholar